In 2012, the company was established in the Greater Philadelphia region - Pennsylvania to elevate the biopharm industry. TechnoPharmSphere has been founded by industry-leading scientists for scientists and we believe in good science for the development of quality medicines to help patients around the world.
We are proud to have been a part of the commendable struggle to utilize the latest advancement in nucleic acid technology for the development of protein, gene, cell, and exosomes therapies. TechnoPharmSphere is proud to have contributed to creating innovative solutions for the diverse and challenging requirements of scientific, industrial, and regulatory communities.
As an integrated service provider, we help you navigate the complexities of developing and manufacturing quality products. By infusing our strong science, industry expertise, and the knowledge of regulatory compliance we are striving to help you every step of the way. We are passionate scientists who aim to help you in the dimensions of technology, analytical methods, cell culture, purification, and drug formulation development. We always strive to deliver supreme practical solutions to set the bar higher for optimized manufacturing processes.
We are skilled in offering comprehensive technical support for regulatory processes by supporting you with content creation and content approval in a fast, reliable, and cost-effective way. With TechnoPharmaSphere, developing and manufacturing high-value medicines is enlightening and reliable.
TechnoPharmaSphere Is Passionate About Helping You To Meet Your Business Goals And Accelerate Medicine Development For Patients Around The World.
The company started as a small firm with operations focused on the development of analytical and biophysical methods including technologies for pharmaceutical product characterization in the USA. We have endured many challenges in this field along the road but our team at TechnoPharmaSphere has never swayed from its mission.
As the demand for enhanced medications to fight a range of diseases increases, the number of biopharm therapeutics is also increasing. However, developing clinical-grade material from these complex molecules is quite challenging owed to a lack of proper analytical technologies, stable formulations, and robust manufacturing processes.
The extensive experience in the full range of biopharm CMC development, interaction with regulatory, intellectual property protection, has helped us to grow into responsible and reliable organization in the biopharma industry. The highest quality science and innovation are the core of our extended services to help clients in the entire CMC development all around the globe, and this is what represents TechnoPharmaSphere!
At TechnoPharmaSphere, we collaborate with your teams in research, development, and manufacturing to effectively deliver enhanced biopharm medicines. Our goal is to help produce clinical and market grade material for the manufacturing of quality medicines. We extensively and rigorously utilize our supreme science and industrial expertise to provide innovative solutions for the full range of product development.
We always aim to share our expertise and donate a percent of our revenue to support the development of the scientific community in education and counseling. We aim to mentor professionals in the challenging field of biopharm to help introduce newer pharmaceutical innovations.
Our passion is to utilize our integrated skills and services to help pharmaceutical innovators and manufacturers to develop effective medicines for patients to live better. Our solid science and direct industry experience in product development are helping to spearhead the development of top-tier medicines promptly with minimum risk.
We are a focused and flexible solutions provider that is dedicated to delivering innovative and cost-effective solutions and for better outcomes. We are committed to doing business with integrity with our employees, partners, suppliers, and clients by respecting their business ideology and culture.
People
Making a positive impact by being inclusive, inspiring, and showing gratitude and passion for what we do at TechnoPharmSphere.
Teamwork
We find breakthrough solutions by professionally collaborating with each client, and respecting everyone’s diverse perspective.
Delivering Outstanding Service
Our continuous improvement, precise execution, and client-oriented services help pave our way to success with quality and excellence.
Making The Connection
We have helped foster trust with our clients by understanding their unique business needs and environments professionally.
Creative Solutions
We create the highest value solutions by incorporating revolutionary approaches to resolve the most complex issues faced by the biopharma industry.
Doing The Right Thing
We aim to win the hearts of both the patients and pharmaceutical stakeholders with honesty, integrity, and fairness. That’s why we are committed to doing the right thing to support youin every action and decision along the challenging journey!
Fatma AlAzzam, PhD
Co-founder and Chief Executive Officer
In 2012, Fatma Alazzam founded TechnoPharmaSphere LLC with the help of her husband and 4 kids which didn't have a great start at the beginning. After her third son was diagnosed with Stage IV Wilms Tumor, sadly passing a year later, she made a promise: TechnoPharmaSphere LLC will be a trusted company to help in the development of drugs to treat diseasesincluding cancer. She believes the cure for cancer is possible by combining correct science and technology.
Fatma earned her PhD in peptide, protein, and lipid biophysics. Her 15 years of experience in biopharm research, formulation, and analytical technologies resulted in several published peer reviewed articles in journals such as PNAS, Biochemistry and JACS. Her experience in studying the structure of peptides and proteins in different formulations has contributed significantly to better understand protein folding and unfolding states. Moreover, Fatma added a good number of novel findings in the formulation of liposome nanoparticles and liposomes’ interaction with vitamins, peptide, and proteins. She has elucidated many protein structural aspects relevant to industrial processes in protein’s liquid, lyophilized, and microglassification formulation. She has developed improvements to analytical characterization methods and biopharm product formulation developments from which she has delivered and written numerous articles.
She has demonstrated a strong portfolio of success leading technology developments for the pharmaceutical, biotechnology, and life science industries in addition to adept at cultivating relationships with our partners, suppliers, and customers.
Wasfi AlAzzam, PhD
Co-Founder and Chief Scientific Officer
Wasfi has extensive experience of more than 15 years working with industry-leading pharmaceutical innovators and manufacturers of biopharm and small molecules. He is currently providing strategic and technical consultation to various TechnoPharmaSphere partners for biopharm product development. Prior to this role, Wasfi was a GSK Fellow in the CMC analytical development GlaxoSmithKline, Pennsylvania. At GSK, he held several roles as an investigator, R&D team leader, CMC matrix team leader, GSK Associate Fellow, and GSK fellow.
Before GSK Wasfi started his career as a process development scientist formulation and delivery lead at Bayer Healthcare-NC. He supported upstream and downstream manufacturing processes in R&D and manufacturing for various liquid and lyophilized formulations in various routes of delivery and devices.
During his experience, he gained wide experience in developing and qualifying analytical and biophysical methods and supported product development in characterization, comparability, cell culture, purifications, drug product formulation, stability studies, and manufacturing. He led various multinational and cross-functional teams, and successfully developed products from proof of concept to clinical trials and post marketing. He was also directly involved in regulatory and clinical development.
Wasfi has extensively contributed towards bringing several products from research into clinical trials and into market such as Ofatumumab®, Nucala®, Tanzeum®, Gamunex®, Thrombate III®, Prolastin®-C, Alphanate®
Wasfi is the founder of the CaSSS International Symposium on the Higher Order Structure of Protein Therapeutics. He has several other contributions to the scientific community by becoming a part of scientific organization committees and forums from academia, regulatory, and industry. He has over 20 peer-reviewed published articles, two patents, and has delivered insightful presentations at several meetings.